Form4insider filings, from the source

Company · CIK 0001628171 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq

Revolution Medicines, Inc. · RVMD

Insider activity reported against this company. All insider holders · On EDGAR ↗

1M3M6M1Y2YAll datashares as filed — not split-adjusted
Open-market buys & salesbuys $0 · 0sales $76.9M · 16net −$76.9M
$10k$10k$1M$1M$100M$100MbuyssalesJun 28Jul 13Jul 28Aug 13Aug 28Sep 13Sep 28

Reported at this company — common stock

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Sep 22, 2026 SForm 4 →Sep 24, 6:00 pm EDTElizabeth M AndersonDirector10,143$193.04$1,958,0164,333−70.1%10b5-1
Sep 22, 2026 MForm 4 →Sep 24, 6:00 pm EDTElizabeth M AndersonDirector5,070$1.12$5,67814,476—10b5-1
Sep 18, 2026 SForm 4 →Sep 22, 6:00 pm EDTAnthony ManciniSee Remarks1,764$196.94$347,40240,352−4.19%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:06 pm EDTAlan B. SandlerChief Development Officer341$199.24$67,94152,868−0.64%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:05 pm EDTAnthony ManciniSee Remarks1,774$199.24$353,44942,116−4.04%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:04 pm EDTStephen Michael KelseySee Remarks5,569$199.24$1,109,554286,307−1.91%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:03 pm EDTMargaret A HornChief Operating Officer4,967$199.24$989,613149,680−3.21%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:02 pm EDTMark A GoldsmithSee Remarks, Director13,988$199.24$2,786,938253,342−5.23%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:01 pm EDTJeff CisliniSVP & General Counsel3,366$199.24$670,63152,541−6.02%10b5-1
Sep 16, 2026 SForm 4 →Sep 18, 6:00 pm EDTJack AndersChief Financial Officer4,053$199.24$807,513119,216−3.29%10b5-1
Sep 11, 2026 SForm 4 →Sep 15, 6:00 pm EDTStephen Michael KelseySee Remarks92,531$202.36$18,724,767291,876−24.1%10b5-1
Sep 11, 2026 MForm 4 →Sep 15, 6:00 pm EDTStephen Michael KelseySee Remarks92,531$41.71$3,859,488384,407—10b5-1
Sep 10, 2026 SForm 4 →Sep 14, 6:03 pm EDTAnthony ManciniSee Remarks15,448$204.16$3,153,80743,890−26.0%10b5-1
Sep 10, 2026 MForm 4 →Sep 14, 6:03 pm EDTAnthony ManciniSee Remarks9,363$33.62$314,78459,338—10b5-1
Sep 8, 2026 SForm 4 →Sep 10, 5:52 pm EDTLorence H. KimDirector17,090$209.82$3,585,8370−100%10b5-1
Aug 31, 2026 SForm 4 →Sep 2, 4:30 pm EDTLorence H. KimDirector56,000$203.24$11,381,28817,090−76.6%10b5-1
Aug 21, 2026 SForm 4 →Aug 25, 4:06 pm EDTJeff CisliniGeneral Counsel56,894$209.24$11,904,24755,907−50.4%10b5-1
Aug 21, 2026 MForm 4 →Aug 25, 4:06 pm EDTJeff CisliniGeneral Counsel56,280$20.00$1,125,687112,801—10b5-1
Aug 21, 2026 SForm 4 →Aug 25, 4:06 pm EDTMark A GoldsmithSee Remarks, Director86,000$209.20$17,991,10761,424−58.3%10b5-1
Aug 21, 2026 MForm 4 →Aug 25, 4:06 pm EDTMark A GoldsmithSee Remarks, Director80,000$4.73$378,400347,330—10b5-1
Jun 29, 2026 SForm 4 →Jul 1, 6:25 pm EDTSushil PatelDirector5,580$187.99$1,048,96721,656−20.5%10b5-1
Jun 29, 2026 MForm 4 →Jul 1, 6:25 pm EDTSushil PatelDirector2,955$37.54$110,93127,236—10b5-1

Reported at this company — derivatives (options, RSUs, warrants)

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Sep 22, 2026 MForm 4 →Sep 24, 6:00 pm EDTElizabeth M AndersonDirector5,070——1,095—10b5-1
Sep 11, 2026 MForm 4 →Sep 15, 6:00 pm EDTStephen Michael KelseySee Remarks92,531$41.71$3,859,48888,069—10b5-1
Sep 10, 2026 MForm 4 →Sep 14, 6:03 pm EDTAnthony ManciniSee Remarks9,363——96,746—10b5-1
Aug 21, 2026 MForm 4 →Aug 25, 4:06 pm EDTJeff CisliniGeneral Counsel56,280——3,500—10b5-1
Aug 21, 2026 MForm 4 →Aug 25, 4:06 pm EDTMark A GoldsmithSee Remarks, Director80,000——344,085—10b5-1
Jun 29, 2026 MForm 4 →Jul 1, 6:25 pm EDTSushil PatelDirector2,955——13,000—10b5-1